EP1054661A1 - Method and device for cleaning of parts of the human body or objects coming into contact with them - Google Patents
Method and device for cleaning of parts of the human body or objects coming into contact with themInfo
- Publication number
- EP1054661A1 EP1054661A1 EP99900899A EP99900899A EP1054661A1 EP 1054661 A1 EP1054661 A1 EP 1054661A1 EP 99900899 A EP99900899 A EP 99900899A EP 99900899 A EP99900899 A EP 99900899A EP 1054661 A1 EP1054661 A1 EP 1054661A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- cysteine proteinase
- agent
- cysteine
- cleaning
- product according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 238000000034 method Methods 0.000 title claims abstract description 32
- 238000004140 cleaning Methods 0.000 title claims abstract description 29
- 108010005843 Cysteine Proteases Proteins 0.000 claims abstract description 102
- 102000005927 Cysteine Proteases Human genes 0.000 claims abstract description 102
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 55
- 239000002852 cysteine proteinase inhibitor Substances 0.000 claims abstract description 41
- 230000000694 effects Effects 0.000 claims abstract description 21
- 230000003213 activating effect Effects 0.000 claims abstract description 17
- 230000009471 action Effects 0.000 claims abstract description 14
- 102100028007 Cystatin-SA Human genes 0.000 claims description 23
- 101710144510 Cysteine proteinase inhibitor Proteins 0.000 claims description 22
- 239000003774 sulfhydryl reagent Substances 0.000 claims description 12
- 230000004913 activation Effects 0.000 claims description 10
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 9
- 239000007787 solid Substances 0.000 claims description 7
- 239000003638 chemical reducing agent Substances 0.000 claims description 5
- 239000000725 suspension Substances 0.000 claims description 4
- 230000000903 blocking effect Effects 0.000 claims 6
- 239000003112 inhibitor Substances 0.000 abstract description 21
- 108090000623 proteins and genes Proteins 0.000 abstract description 10
- 102000004169 proteins and genes Human genes 0.000 abstract description 9
- 235000018102 proteins Nutrition 0.000 abstract description 8
- 230000002087 whitening effect Effects 0.000 abstract description 7
- 102000004190 Enzymes Human genes 0.000 abstract description 5
- 108090000790 Enzymes Proteins 0.000 abstract description 5
- 230000008901 benefit Effects 0.000 abstract description 3
- 230000006378 damage Effects 0.000 abstract description 2
- 239000000047 product Substances 0.000 description 31
- 239000013543 active substance Substances 0.000 description 17
- 239000002502 liposome Substances 0.000 description 17
- 239000003814 drug Substances 0.000 description 15
- 108010084457 Cathepsins Proteins 0.000 description 14
- 102000005600 Cathepsins Human genes 0.000 description 14
- 229940079593 drug Drugs 0.000 description 14
- 238000002360 preparation method Methods 0.000 description 11
- 239000004365 Protease Substances 0.000 description 9
- 108090000613 Cathepsin S Proteins 0.000 description 7
- 235000018417 cysteine Nutrition 0.000 description 7
- 239000003826 tablet Substances 0.000 description 7
- 102100035654 Cathepsin S Human genes 0.000 description 6
- 108090000526 Papain Proteins 0.000 description 6
- 238000013270 controlled release Methods 0.000 description 6
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 6
- 235000019834 papain Nutrition 0.000 description 6
- 229940055729 papain Drugs 0.000 description 6
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 6
- 238000000746 purification Methods 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 102000012193 Cystatin A Human genes 0.000 description 5
- 108010061641 Cystatin A Proteins 0.000 description 5
- 230000002378 acidificating effect Effects 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 102000035195 Peptidases Human genes 0.000 description 4
- 108091005804 Peptidases Proteins 0.000 description 4
- 230000002939 deleterious effect Effects 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 108010032088 Calpain Proteins 0.000 description 3
- 102000007590 Calpain Human genes 0.000 description 3
- 108010061635 Cystatin B Proteins 0.000 description 3
- 102100026891 Cystatin-B Human genes 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 108090000144 Human Proteins Proteins 0.000 description 3
- 102000003839 Human Proteins Human genes 0.000 description 3
- 102000004877 Insulin Human genes 0.000 description 3
- 108090001061 Insulin Proteins 0.000 description 3
- 102000010631 Kininogens Human genes 0.000 description 3
- 108010077861 Kininogens Proteins 0.000 description 3
- 108010026774 Salivary Cystatins Proteins 0.000 description 3
- 229920002807 Thiomer Polymers 0.000 description 3
- 239000000227 bioadhesive Substances 0.000 description 3
- -1 calcium-activated cysteine Chemical class 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 229940112822 chewing gum Drugs 0.000 description 3
- 235000015218 chewing gum Nutrition 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 238000005538 encapsulation Methods 0.000 description 3
- 229940125396 insulin Drugs 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 210000004379 membrane Anatomy 0.000 description 3
- 210000002200 mouth mucosa Anatomy 0.000 description 3
- 210000004877 mucosa Anatomy 0.000 description 3
- 230000007935 neutral effect Effects 0.000 description 3
- 239000006072 paste Substances 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 239000000825 pharmaceutical preparation Substances 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000000606 toothpaste Substances 0.000 description 3
- TWBNMYSKRDRHAT-RCWTXCDDSA-N (S)-timolol hemihydrate Chemical compound O.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1 TWBNMYSKRDRHAT-RCWTXCDDSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 108010076667 Caspases Proteins 0.000 description 2
- 102000011727 Caspases Human genes 0.000 description 2
- 108090000712 Cathepsin B Proteins 0.000 description 2
- 102000004225 Cathepsin B Human genes 0.000 description 2
- 108010061642 Cystatin C Proteins 0.000 description 2
- 102100026897 Cystatin-C Human genes 0.000 description 2
- 102000004157 Hydrolases Human genes 0.000 description 2
- 108090000604 Hydrolases Proteins 0.000 description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- 102000018968 Salivary Cystatins Human genes 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 208000007107 Stomach Ulcer Diseases 0.000 description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 150000001447 alkali salts Chemical class 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 239000003599 detergent Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 238000005194 fractionation Methods 0.000 description 2
- 201000005917 gastric ulcer Diseases 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 239000000017 hydrogel Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- 230000003232 mucoadhesive effect Effects 0.000 description 2
- 210000004400 mucous membrane Anatomy 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 235000019833 protease Nutrition 0.000 description 2
- 230000002797 proteolythic effect Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 210000003296 saliva Anatomy 0.000 description 2
- 239000000344 soap Substances 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 229960004605 timolol Drugs 0.000 description 2
- 229940034610 toothpaste Drugs 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
- 229960002675 xylitol Drugs 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- FJPHHBGPPJXISY-UHFFFAOYSA-N 2-[[2-[[2-[(2-aminoacetyl)amino]acetyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-5-(diaminomethylideneamino)pentanoic acid Chemical compound NC(N)=NCCCC(C(O)=O)NC(=O)C(NC(=O)CNC(=O)CN)CC1=CC=C(O)C=C1 FJPHHBGPPJXISY-UHFFFAOYSA-N 0.000 description 1
- SUBDBMMJDZJVOS-UHFFFAOYSA-N 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole Chemical compound N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- 241000605087 Anguillid perhabdovirus Species 0.000 description 1
- 229930003347 Atropine Natural products 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108010004032 Bromelains Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229940122072 Carbonic anhydrase inhibitor Drugs 0.000 description 1
- 229940123003 Cathepsin inhibitor Drugs 0.000 description 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 102000015833 Cystatin Human genes 0.000 description 1
- 102100028188 Cystatin-F Human genes 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 108090000270 Ficain Proteins 0.000 description 1
- 241000219146 Gossypium Species 0.000 description 1
- 208000005100 Herpetic Keratitis Diseases 0.000 description 1
- 101000916688 Homo sapiens Cystatin-F Proteins 0.000 description 1
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- 241000251551 Lampetra fluviatilis Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010073938 Ophthalmic herpes simplex Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 101710193050 Papain inhibitor Proteins 0.000 description 1
- LRJOMUJRLNCICJ-JZYPGELDSA-N Prednisolone acetate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O LRJOMUJRLNCICJ-JZYPGELDSA-N 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 241001346815 Spongia officinalis Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 238000001720 action spectrum Methods 0.000 description 1
- 239000003732 agents acting on the eye Substances 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 150000001413 amino acids Chemical group 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 230000001078 anti-cholinergic effect Effects 0.000 description 1
- 229940019748 antifibrinolytic proteinase inhibitors Drugs 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229960000396 atropine Drugs 0.000 description 1
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 1
- PFOLLRNADZZWEX-FFGRCDKISA-N bacampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)[C@H](C(S3)(C)C)C(=O)OC(C)OC(=O)OCC)=CC=CC=C1 PFOLLRNADZZWEX-FFGRCDKISA-N 0.000 description 1
- 229960002699 bacampicillin Drugs 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000035587 bioadhesion Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 235000019835 bromelain Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 239000003489 carbonate dehydratase inhibitor Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 230000030570 cellular localization Effects 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 230000001055 chewing effect Effects 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 229960001815 cyclopentolate Drugs 0.000 description 1
- SKYSRIRYMSLOIN-UHFFFAOYSA-N cyclopentolate Chemical compound C1CCCC1(O)C(C(=O)OCCN(C)C)C1=CC=CC=C1 SKYSRIRYMSLOIN-UHFFFAOYSA-N 0.000 description 1
- 108050004038 cystatin Proteins 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000008260 defense mechanism Effects 0.000 description 1
- 210000001787 dendrite Anatomy 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- OUZWUKMCLIBBOG-UHFFFAOYSA-N ethoxzolamide Chemical class CCOC1=CC=C2N=C(S(N)(=O)=O)SC2=C1 OUZWUKMCLIBBOG-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- XUFQPHANEAPEMJ-UHFFFAOYSA-N famotidine Chemical compound NC(N)=NC1=NC(CSCCC(N)=NS(N)(=O)=O)=CS1 XUFQPHANEAPEMJ-UHFFFAOYSA-N 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 235000019836 ficin Nutrition 0.000 description 1
- POTUGHMKJGOKRI-UHFFFAOYSA-N ficin Chemical compound FI=CI=N POTUGHMKJGOKRI-UHFFFAOYSA-N 0.000 description 1
- 235000019688 fish Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- GPRLSGONYQIRFK-UHFFFAOYSA-N hydron Chemical compound [H+] GPRLSGONYQIRFK-UHFFFAOYSA-N 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 239000007942 layered tablet Substances 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 230000002132 lysosomal effect Effects 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000002324 mouth wash Substances 0.000 description 1
- 229940051866 mouthwash Drugs 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 229960000381 omeprazole Drugs 0.000 description 1
- 229940023490 ophthalmic product Drugs 0.000 description 1
- 210000001711 oxyntic cell Anatomy 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- ZEMIJUDPLILVNQ-ZXFNITATSA-N pivampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)[C@H](C(S3)(C)C)C(=O)OCOC(=O)C(C)(C)C)=CC=CC=C1 ZEMIJUDPLILVNQ-ZXFNITATSA-N 0.000 description 1
- 238000005498 polishing Methods 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 229960002800 prednisolone acetate Drugs 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 235000019419 proteases Nutrition 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 230000001185 psoriatic effect Effects 0.000 description 1
- 229940085606 rembrandt Drugs 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000012265 solid product Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000006190 sub-lingual tablet Substances 0.000 description 1
- 229940098466 sublingual tablet Drugs 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 230000036964 tight binding Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 229940078499 tricalcium phosphate Drugs 0.000 description 1
- 229910000391 tricalcium phosphate Inorganic materials 0.000 description 1
- 235000019731 tricalcium phosphate Nutrition 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
- C11D3/00—Other compounding ingredients of detergent compositions covered in group C11D1/00
- C11D3/16—Organic compounds
- C11D3/38—Products with no well-defined composition, e.g. natural products
- C11D3/386—Preparations containing enzymes, e.g. protease or amylase
-
- C11D2111/18—
-
- G—PHYSICS
- G02—OPTICS
- G02C—SPECTACLES; SUNGLASSES OR GOGGLES INSOFAR AS THEY HAVE THE SAME FEATURES AS SPECTACLES; CONTACT LENSES
- G02C13/00—Assembling; Repairing; Cleaning
- G02C13/008—Devices specially adapted for cleaning contact lenses
Definitions
- the object of the invention is a method and a product for cleaning of a person ' s body parts or objects coming into contact with said body parts , based on the use of a cysteine proteinase or an activating agent therefor .
- Cysteine proteinases are proteolytic enzymes which possess a cysteine residue in their active site. For the existence in an active reduced form these enzymes need an external 0 sulfhydryl reagent.
- the mammalian cysteine proteinases belong to the cathepsin family and among them at least cathepsins B, H, L, S, 0, U, and N have been purified and classified.
- the first mammalian cysteine proteinase to be characterized was cathepsin B (Suominen, J. & Hopsu-Havu, 5 V.K.: Cathepsin B in the thyroid gland. Acta chem. Scand. 1971:25:2531).
- cysteine proteinases such as ficin, bromelain and papain (Jarvinen, M. , Rinne, A.: Human spleen cysteine proteinase inhibitor. Purification, fractionation into isoelectric variants and some properties of the variants . Biochim Biophys Acta 1982:708:210-217).
- cysteine proteinases in the plant kingdom and those found in mammalians are closely related to each other as to their physical and biochemical properties .
- Papain is classically used in research work as a cysteine proteinase employed routinely in tests and as a proteinase for comparative research work concerning mammalian cysteine proteinases and their inhibitors (the reference books, the inventor' s own unpublished and published results (Ari Rinne and Mikko Jarvinen 1976-1997)).
- mammalian cysteine proteinases The most numerous and best known mammalian cysteine proteinases are considered to belong to the cathepsin family. However, the mammalian cysteine proteinase inhibitors are divided into several families by their structure and mode of action.
- cysteine proteinases are further known calcium-activated cysteine proteinases, which are considered to belong to the calpain family.
- Their inhibitors are called calpastatins (M. Nakamura, S. Imajoh-Ohmi, K. Suzuki and S. Kawashima: An endogenous inhibitor of calcium-activated neutral proteinase in UMX 7.1 Hamster Dystrophy. Muscle & Nerve 14:701-708, 1991). They are also inhibited by the cathepsin inhibitor kininogen .
- caspases possess cysteine proteinase activity that can be inhibited (Nancy A Thornberry and Yuri Lazebnik: "Caspases: Enemies Within", Science vol. 281, 28 Aug 1998; Ari Rinne 's unpublished results ) .
- Cysteine proteinases have the property of dissoluting biological material, which properties can be inhibited by using inhibitors (toothpastes Rembrant® and Yotuel®, Kirschke, H., Rawlings, N.B., Barrett, A.J.: Lysosomal cysteine proteinases, Academic Press, London 1995 and the inventor' s own unpublished results.)
- cystatin A Human protein data [A. Haeberli, editor, VCH Verlag, Weinheim] , 3.
- NPI Neutral cysteine proteinase inhibitor
- cystatin B or stefin B.
- Type I (Rinne, A., Rinne, R., Jarvinen, M. : Cystatin B. Human protein data [A. Haeberli, editor, VCH Verlag, Weinhei ] , 3. Installment 1995).
- v-trace which is called cystatin C. (Type II) (Abrahamson, M. : Human cysteine proteinase inhibitors. Isolation, physiological importance, inhibitory mechanism, gene structure and relation to hereditary cerebral hemorrhage. Scand J Clin Lab Invest 1988: 48:suppl 191:21-31) .
- Cystatin S. (Type II) (Isemura, S., Saitoh, E., Sanada, K. : Characterization and amino acid sequence of a new acidic cysteine proteinase inhibitor (Cystatin SA) structurally closely related to cystatin S, from human whole saliva. J Biochem 1987: 102:693-704).
- the type I lacks sulfur bridges.
- the type II has two sulfur bridges.
- the type III has three structures of the type II and a chain responsible for kininogen activity. Cysteine proteinase inhibitors are found particularly in cellular structures which have a role in the defense mechanism, such as in granulocytes, stratified squamous epithelia, dendrites as well as in histiocytic reticular cells and in the reserve cells in prostata. (Davies, M.E. and Barrett, A.J.. Immunolocalization of human cysteins in neutrophils and lymphocytes. Histochemistry, 80:373-377, 1984).
- cysteine proteinase inhibitors In addition to the natural cysteine proteinase inhibitors, also synthetic peptide cysteine proteinase inhibitors have been made. (Bromme, D., Rinne, R., Kirschke, H.: Tight-binding inhibition of cathepsin S by cystatins . Bio ed Biochim Acta 1991:150:631-635). Cysteine proteinase inhibitors are also found in the skin of poikilothermic animals, such as salmon and river lamprey (for example the recently found so called troms family; own unpublished results of the inventor' s team) . Cysteine proteinase inhibitors are known to inhibit the reproduction of microbes (bacteria and viruses) and/or the associated destruction of tissues (Rinne, A.
- Cystatin A Human protein data [A. Haeberli, editor, VCH Verlag, Weinheim] , 3. Installment 1995; Bj ⁇ rck, L., Grubb, A. and Kjellen, L. (1990) Cystatin C, a human proteinase inhibitor, blocks replication of Herpes simplex virus. J Virol 64, 941-943; Bj ⁇ rck, L., Akesson, P., Bohus , M., Trojnar, J.,
- cysteine proteinase inhibitors found endogenously in the mouth (in the saliva and the mucosa) make a contribution to the inhibition of cysteine proteinases.
- the ACPI for example, is known to be reduced or lost in an inflamed or cariotic mouth (Finnish 6 patent FI 96743 and inventor's own unpublished results).
- Controlling the rate and timing of the release of an active agent, generally a medicament, from a pharmaceutical preparation is a common practice in the development of drugs.
- the controlled release of an active agent is applied, for example, for preparations which do not withstand the action of the gastric juice.
- a tablet is coated with a membrane which is not degraded until in the small intestine, in which case the drug can be protected against the deleterious effects of the acidic environment in the stomach.
- Many kinds of pharmaceutical preparations, in which the drug is released at a controlled rate are also used in ophthalmology.
- the aim in their development has been to obtain a relatively slow release of the drug from the carrier.
- a suitable form of preparation it is possible to control the rate of release in both directions.
- the drug When the so called pro- drugs are used, the drug itself is bound to a carrier in such a manner that the complex is inactive and the activation does not occur until, for example, at the mucosa upon the cleavage of the bond between the carrier and the drug.
- examples of such preparations are among others piv- and bacampicillin, both of which are clinically used preparations .
- the drug can also be activated by the pH in its environment.
- omeprazole a drug which is used in the treatment of gastric ulcer and which does not become active until upon contact with the hydrogen ion-producing parietal cells in the stomach.
- the pharmaceutical dosage form of a drug can be designed to release the active agent relatively quickly in the oral mucosa.
- the originally solid preparation disintegrates on the oral mucosa at a conspicuously fast rate so that the effect of the drug in the bloodstream is obtained as early as in 2-3 minutes.
- Pepcidin Rapitab tablet which rapidly releases the drug upon contact with oral excretions; the dissolution of the tablet on the oral mucosa takes only a few tens of seconds .
- a two-layered tablet allows the release of desired pharmacologically active agents in a chosen order.
- the outer layer of the tablet can be adapted to dissolve rapidly upon contact with oral excretions, whereupon the agent mixed therein is delivered quickly in the mouth; by employing excipients in the core of the tablet, the core can be adapted to dissolve at a slower rate, which results in a slower release and a slower onset of the effects of the active agents mixed therein.
- preparations comprising more than two layers, which result in the ability to control the respective order of release and the onset of the effects of the active agent when the product is held on the oral mucous membrane .
- liposomes allow the encapsulation of, among other things, drugs and many other biologically active agents within their interior, thereby making it possible to have a desired influence on the spectrum of actions of the respective agent in the body.
- composition of the liposomal membrane, encapsulation efficiency or the ability of the liposome to encapsulate the desired active agent within its interior, the stability of the preparation, the release rate of the active agent, the distribution of the liposomal preparation within the body, the size of the liposome and its surface electric 8 charge contribute, besides of other factors, to the properties of the complex composed of the liposome and the encapsulated agent, thereby making the application of the combination in various situations flexible.
- Insulin can be mentioned as an example of a protein structure which is rather simple to encapsulate in the liposome.
- a thin membrane can be made of lechitin and cholesterol.
- cysteine proteinases The enzymatic activity of cysteine proteinases has been exploited in the art in a cleaning and whitening toothpaste (Rembrandt®, Yotuel®) .
- a cleaning and whitening toothpaste (Rembrandt®, Yotuel®) .
- papain is a foreign protein to the mammalian body and in long term use of it is known to cause allergy at least (observations made by Ari Rinne in his own laboratory during the years 1975-1998 and general lecture knowledge in the medical faculties, e.g. in eye diseases).
- papain is active at an acidic pH but not at a physiological pH in the oral area, as for example body' s own cathepsin S.
- Yotuel® chewing gum which contains, among other things, xylitol and papain as a whitening agent, has appeared on the market quite recently.
- the invention concerns a method for cleaning of a person's body parts, except for the teeth, or objects coming into contact with said body parts.
- the body' s own cysteine proteinase is contacted with said body part or object.
- the invention concerns a hygiene product intended for cleaning of a person' s body parts, except for the teeth, or objects coming into contact with said body parts, said product containing a cysteine proteinase and a necessary carrier.
- the cysteine proteinase is one of the body's own cysteine proteinases .
- the invention concerns a method for cleaning of a person's body parts or objects coming into contact with said body parts.
- the method is characterized in that an agent activating the body' s own cysteine proteinase is contacted with said body part or object.
- the invention concerns a hygiene product intended for cleaning of a person' s body parts or objects coming into contact with said body parts.
- the product is characterized in that it comprises an agent activating the body's own cysteine proteinase and optionally a carrier.
- cysteine proteinase or cysteine proteinase inhibitor refers to substances purified by techniques in the art of protein chemistry as well as produced by molecular biological techniques . Most of such cysteine proteinases belong to the cathepsin, caspasine or calpain family. 10
- the body's own cysteine proteinase in the method is brought into contact with the object to be cleaned.
- the cysteine proteinase is activated by contacting it with a sulfhydryl reagent, such as cysteine.
- a sulfhydryl reagent such as cysteine.
- the pH is suitable to the activation of the respective cysteine proteinase.
- the pH is suitably adjusted, if necessary, in order to activate the cysteine proteinase.
- Various procedures are available for the activation.
- the cysteine proteinase can also be pre-activated .
- cysteine proteinase activity can be blocked by delivering a pH-controlling agent and/or body' s own cysteine proteinase inhibitor onto the object to be cleaned, at a moment when the cysteine proteinase has acted sufficiently long.
- the action of the cysteine proteinase can be blocked by releasing onto the object to be cleaned, a pH-controlling agent given concurrently with the cysteine proteinase and/or body' s own cysteine proteinase inhibitor.
- the hygiene product according to the invention intended for cleaning the person's body parts or objects coming into contact with said body parts, said product comprising the body' s own cysteine proteinase and a necessary carrier, can, in principle, be of any type.
- it can be solid; a solution; a suspension or semi-solid.
- the product comprises also a sulfhydryl reagent or some other reductant necessary for the activation of the cysteine proteinase. If the ambient pH of the object to be cleaned is unfavourable for the activation of the cysteine proteinase it is advisable that the product also contains a pH-controlling substance. 11
- an agent which blocks the cysteine proteinase can be a pH-controlling agent (or an agent which blocks the active state of the cysteine proteinase) or any of the body' s own cysteine proteinase inhibitors .
- the release of the agent which blocks the cysteine proteinase after a specified time has elapsed can be accomplished by employing any of the techniques known in the art of controlled release.
- the product can also comprise many of the body' s own cysteine proteinases and possibly many of the body' s own cysteine proteinase inhibitors .
- the object to be cleaned which is a person's body part, or a object co ing into contact with said body part, is contacted with an agent activating the body's own cysteine proteinase.
- an agent activating the body's own cysteine proteinase In this alternative, no cysteine proteinase is added.
- a reducing agent for example a sulfhydryl reagent, such as cysteine or calcium.
- the pH is suitable for the activation of the cysteine proteinase. If necessary, the pH can be adjusted to a suitable level for the activation of cysteine proteinase.
- activating agents other suitable agents can also be used.
- the plain activating agent is, for example, suitable for cleaning of a person's teeth.
- cleaning shall, as far as teeth are concerned, also be understood to encomapss “whitening” .
- cysteine proteinase activity can be blocked by delivering a pH-controlling agent and/or body' s own 12 cysteine proteinase inhibitor onto the object to be cleaned, at a moment when the cysteine proteinase has acted sufficiently long.
- the action of the cysteine proteinase can be blocked by releasing onto the object to be cleaned, a pH-controlling agent given concurrently with the cysteine proteinase and/or body' s own cysteine proteinase inhibitor.
- the hygiene product according to the invention intended for cleaning the person's body parts such as teeth, said product comprising an agent activating the body' s own cysteine proteinase, and optionally a necessary carrier, can, in principle, be of any type.
- it can be solid such as a chewing gum or tablet; a solution; a suspension or semi-solid such as, for example, a toothpaste.
- the product comprises as activating agent a sulfhydryl reagent or some other reductant. If the ambient pH of the object to be cleaned is unfavourable for the activation of the cysteine proteinase, it is advisable that the product also contains a pH- controlling substance.
- an agent which blocks the cysteine proteinase can be a pH-controlling agent (or an agent which blocks the active state of the cysteine proteinase) or any of the body' s own cysteine proteinase inhibitors .
- the release of the agent which blocks the cysteine proteinase after a specified time has elapsed can be accomplished by employing any of the techniques known in the art of controlled release.
- the methods according to the invention are especially 13 useful for cleaning of the oral regions or the skin, or for cleaning of prostheses, various treatment devices etc.
- active agents the body's own cysteine proteinase and/or an activating agent therefor
- sweets such as chewing gum
- foodstuffs and drinks chewing tablets
- mouthwash for oral hygiene
- cleaning emulsions for the skin and the hair cottons and towels for cleaning of the skin
- liquids and powders for the cleaning of prostheses, for example dental prostheses
- auxiliary devices such as contact lenses, glases, hearing aids, items of clothing, vessels and (medical or dental) instruments.
- the disk for cleaning and whitening of teeth located at the tip of the dentist's drill, can be coated with the proteins in question.
- a usual tooth brush or bath sponge can also be coated with these agents .
- natural human cathepsin S (this can be produced for example by molecular biological techniques), which is active at the physiological pH prevailing on the object to be cleaned.
- a sulfhydryl reagent for example cysteine, which is released on the object to be cleaned, from granules, see below.
- cathepsin S With the assistance of an externally added sulfhydryl reagent cathepsin S becomes biologically active and performs proteolytic cleaning of the object to be cleaned.
- the long-term and possibly deleterious proteolytic activity of cathepsin S is inhibited with the release after a specified time on the object to be cleaned of (a) human cysteine proteinase inhibitor(s) added to the product.
- cysteine proteinase inhibitors in inhibiting the growth of pathogenic micro-organisms, which is known in the art, is also taken advantage of.
- cysteine proteinase inhibitors known natural human cysteine 14 proteinase inhibitors are employed.
- the products can also be prepared so that, for example, human cathepsins B, H or L are used as the natural cysteine proteinase, in which case the product has to be made such that the excipients in the product convert the object to be cleaned transiently acidic, under which conditions the respective cathepsins are biologically active.
- human cathepsins B, H or L are used as the natural cysteine proteinase, in which case the product has to be made such that the excipients in the product convert the object to be cleaned transiently acidic, under which conditions the respective cathepsins are biologically active.
- new recently discovered human cysteine cathepsins, such as 0, U, K etc., can be used once their activity ranges have been exactly determined.
- proteins (cysteine proteinases and their inhibitors) associated with this invention can be produced by purifying them directly from human tissues or by using molecular biological techniques.
- the pH in the mixture and in the object to be cleaned should return again to a physiological value secondarily in connection with the release of the inhibitor.
- the potency of the respective exogenously added natural cathepsins is exhausted and the natural externally added inhibitors together with the inhibitors optionally already present in the object to be cleaned, secure additionally the cessation of the proteolysis, which is deleterious in the body.
- the excipients in question (cysteine proteinases and their inhibitors) are added to products which are known per se (for example cleaning liquids for contact lenses). Many variations can be made in the basic products . Modifications and fine-tuning can be made by using cysteine proteinases which differ somewhat in their biological properties. Similarly, representatives of various cysteine proteinase inhibitor families can be used.
- Cathepsins and the sulfhydryl reagent are packaged into the different phases of the products by employing for example liposomes (the pH is dependent upon the cathepsin 15 employed), from which these are released at a controlled rate as the conditions in the environment change upon bringing the liposomes into contact with the object to be cleaned.
- the retention time on the object to be cleaned is dependent among other things on their electric charge
- Liposomal ophthalmic drug delivery III. Pharmacodynamic and biodisposition studies of atropine . Int J Pharm 1989:55:105-113; Barber, R.F., Shek, P.N.: Tear-induced release of liposome-entrapped agents. Int J Pharm 1990:60:219-227; Lee, V.H.L., Urrea , P.T., Smith, R.E., Schantzlin, D.J. : Ocular drug bioavailability from topically applied liposomes . Surv Ophthalmol 1985:29:335-348; Guo, L.S.S., Redema , C.T., Radhakrisnan, R.
- a paced action can be obtained also by using a so called hydrogel, from which the active agent is slowly released by diffusion (Kupferman, A., Ryan, W.J., Leibowitz, H.M.: Prolongation of anti-inflammatory effect of prednisolone acetate. Influence of formulation in high-viscosity gel. Arch Ophthalmol 1981:99:2028-2029; Lewis, R.A. , Schoenwald, R.D., Eller, M.G. , Barfknecht, C.F., Phelps , CD.:
- Ethoxzolamide analogue gel A topical carbonic anhydrase inhibitor. Arch Ophthamol 1984:102:1821-1824; Urtti, A.: Silman uudet laakemuodot . In: Biofarmasia 1986 Kuopio. Gummerus Oy, Jyvaskyla 1986:44-53). If various matrices (carrier phases) are included in the same preparation, the release of active agents admixed therein is accomplished with distinct rates and different durations of existence on the object to be cleaned.
- the active agents can be packaged in a layered manner.
- the pace of the release can be controlled to obtain a more defined and 17 clear result by packaging the active agents in different materials .
- composition of a paste can be the following:
- Abrasive and polishing agents for example calcium carbonate or tricalcium phosphate, ca 50 %
- Binder for example aqueous silica or sodium carboxymethylcellulose, ca 3 % 3.
- Humidifiers for example sorbitol or glycerol, ca 30 %
- Flavor and aroma for example saccharine or xylitol (according to current trend salmiac), ca 1 % 7. 0,001 % cysteine cathepsin as such or packaged into liposomes
- cysteine proteinases are used to obtain cleaning and whitening and, on the other hand, the excessive and probably deleterious action of these cysteine proteinases upon tissues is blocked by using exogenously added natural cysteine proteinase inhibitors .
- the enzyme kinetics of these proteins is well known
- both the cysteine proteinases and their inhibitors delivered externally into the body are body' s own proteins, therefore the risk of sensitization is small; this is in contrast to the use of the corresponding proteinases and their inhibitors, which are recognized as foreign by the body and derived for example from the plant kingdom.
Abstract
The invention relates to a method and a product for cleaning of a person's body parts or objects coming into contact with said body parts. In oral hygiene products, cysteine proteinases have been shown to have a cleaning and whitening action on the teeth. However, tissues suffer damage from an extended action of cysteine proteinases. In this invention, natural human cysteine proteinases are employed for cleaning and whitening purposes and this activity can be blocked by natural cysteine proteinase inhibitors, which are released secondarily from the products at a later stage. According to the invention, to the hygiene product can be added the body's own cysteine proteinase and/or an agent activating said cysteine proteinase. The plain activating agent can also be used, because the activating agent activates the cysteine proteinase present in its biological environment. In particular, the use of natural cysteine proteinases and their inhibitors provides the advantage that they are man's own proteins, and therefore the risk of allergization is minimized. In addition, their enzyme kinetics is presently well known.
Description
METHOD AND DEVICE FOR CLEANING OF PARTS OF THE HUMAN BODY OR OBJECTS COMING INTO CONTACT WITH THEM
The object of the invention is a method and a product for cleaning of a person ' s body parts or objects coming into contact with said body parts , based on the use of a cysteine proteinase or an activating agent therefor .
5 PRIOR ART
Cysteine proteinases and their inhibitors
Cysteine proteinases are proteolytic enzymes which possess a cysteine residue in their active site. For the existence in an active reduced form these enzymes need an external 0 sulfhydryl reagent. The mammalian cysteine proteinases belong to the cathepsin family and among them at least cathepsins B, H, L, S, 0, U, and N have been purified and classified. The first mammalian cysteine proteinase to be characterized was cathepsin B (Suominen, J. & Hopsu-Havu, 5 V.K.: Cathepsin B in the thyroid gland. Acta chem. Scand. 1971:25:2531). These are distributed throughout the body but they are found especially in the kidneys, liver, and macrophages (Rinne, A., Jarvinen, M., Kirschke, H., iederanders , B., Hopsu-Havu, V.K. : Demonstration of 0 cathepsins H and L in rat tissues. Biomed Biochim Acta 1986:45;11-12:1465-1476) . A part of them are proteolytically active in acidic pH values but a part are active in physiological pH values, such as cathepsin S. (Kirschke, H. , Wiederanders, B., Brδmme, D., Rinne, A.:
25 Cathepsin S from bovine spleen. Purification, distribution, intracellular localization and action on proteins. Biochem J 1989:264:467-473, and Kirschke, H., Rawlings, N.D., Barrett, A.J.: Lysoso al cysteine proteinases. Academic Press, London 1995).
30 In the plant kingdom, there are found cysteine proteinases
such as ficin, bromelain and papain (Jarvinen, M. , Rinne, A.: Human spleen cysteine proteinase inhibitor. Purification, fractionation into isoelectric variants and some properties of the variants . Biochim Biophys Acta 1982:708:210-217).
The cysteine proteinases in the plant kingdom and those found in mammalians are closely related to each other as to their physical and biochemical properties . Papain is classically used in research work as a cysteine proteinase employed routinely in tests and as a proteinase for comparative research work concerning mammalian cysteine proteinases and their inhibitors (the reference books, the inventor' s own unpublished and published results (Ari Rinne and Mikko Jarvinen 1976-1997)).
The most numerous and best known mammalian cysteine proteinases are considered to belong to the cathepsin family. However, the mammalian cysteine proteinase inhibitors are divided into several families by their structure and mode of action.
Among the mammalian cysteine proteinases are further known calcium-activated cysteine proteinases, which are considered to belong to the calpain family. Their inhibitors are called calpastatins (M. Nakamura, S. Imajoh-Ohmi, K. Suzuki and S. Kawashima: An endogenous inhibitor of calcium-activated neutral proteinase in UMX 7.1 Hamster Dystrophy. Muscle & Nerve 14:701-708, 1991). They are also inhibited by the cathepsin inhibitor kininogen . Also so called caspases possess cysteine proteinase activity that can be inhibited (Nancy A Thornberry and Yuri Lazebnik: "Caspases: Enemies Within", Science vol. 281, 28 Aug 1998; Ari Rinne 's unpublished results ) .
Cysteine proteinases have the property of dissoluting biological material, which properties can be inhibited by
using inhibitors (toothpastes Rembrant® and Yotuel®, Kirschke, H., Rawlings, N.B., Barrett, A.J.: Lysosomal cysteine proteinases, Academic Press, London 1995 and the inventor' s own unpublished results.)
The following are the most important and best known so called "classical" natural (originating from the body) families of cysteine proteinase inhibitors:
1. Epidermal-SH-proteinase inhibitor or acid cysteine proteinase inhibitor (ACPI) or stefin A. This inhibitor was simultaneously discovered in the beginning of the 1970' by Hayashi and Jarvinen (Hayashi, H. (1975): The intracellular neutral SH-dependent protease associated with inflammatory reactions. Int. Rev. Cytol., 40:101-151; Jarvinen, M. and Hopsu-Havu, V.K. (1975): α-N-Benzoylarginine-2-naphthyl- amide hydrolase (Cathepsin Bl?) from rat skin. II. Purification of the enzyme and demonstration of two inhibitors in the skin. Acta Chem Scand B, 29:772-780). It is aimed to have this inhibitor named internationally as cystatin A. (Type I) (Rinne, A: Cystatin A. Human protein data [A. Haeberli, editor, VCH Verlag, Weinheim] , 3.
Installment 1995; Green, G.D.J., Kembhavi . A.A. , Davies, M.L., Barrett, A.J.: Cystatin-like cysteine proteinase inhibitors from human liver. Bioche J 1984:218:939-946; Rinne, A.: Epidermal SH-protease Inhibitor. Occurrence in human and rat tissues and in human neoplasms. Thesis. Acta Univ Ouluensis, Ser D, Medica No. 41, Oulu 1979).
2. Another small-molecular cysteine proteinase inhibitor, which was electroneutral at pH-values 6.0-6.5, was discovered at the end of the 1970' (A. Rinne, M. Jarvinen, J. Martikainen, M. Alavaikko und 0. Rasanen: ϋber das Vorkommen des epidermalen SH-Protease-Inhibitors im lymphatischen Gewebe . Verh. Anat. Ges . 75, S. 573-574 (1981); Jarvinen, M. , Rinne, A.: Human spleen cysteine proteinase inhibitor. Purification, fractionation into isoelectric variants and some properties of the variants.
Biochim Biophys Acta 1982:708:210-217). Neutral cysteine proteinase inhibitor (NCPI) or cystatin B or stefin B. (Type I) (Rinne, A., Rinne, R., Jarvinen, M. : Cystatin B. Human protein data [A. Haeberli, editor, VCH Verlag, Weinhei ] , 3. Installment 1995).
3. v-trace, which is called cystatin C. (Type II) (Abrahamson, M. : Human cysteine proteinase inhibitors. Isolation, physiological importance, inhibitory mechanism, gene structure and relation to hereditary cerebral hemorrhage. Scand J Clin Lab Invest 1988: 48:suppl 191:21-31) .
4. Cystatin S. (Type II) (Isemura, S., Saitoh, E., Sanada, K. : Characterization and amino acid sequence of a new acidic cysteine proteinase inhibitor (Cystatin SA) structurally closely related to cystatin S, from human whole saliva. J Biochem 1987: 102:693-704).
5. Kininogen. (Type III). (Jarvinen, M. , Hopsu-Havu, V.-K.: α-N-benzoylarginine-2-naphthylamide hydrolase (cathepsin Bl?) from rat skin. II. Purification of the enzyme and demonstration of two inhibitors in the skin. Acta Chem Scand 1975 :B: 29 : 772-780 ) .
6. "Psoriasis inhibitor", for which we have recently proposed the name squamin . (Type ? (not classified so far) (Jarvinen, M. , Rinne, A., Hopsu-Havu, V.K.: Partial purification and some properties of a new papain inhibitor from psoriatic scales. J Invest Dermatol 1984:82:471-476).
The type I lacks sulfur bridges. The type II has two sulfur bridges. The type III has three structures of the type II and a chain responsible for kininogen activity. Cysteine proteinase inhibitors are found particularly in cellular structures which have a role in the defense mechanism, such as in granulocytes, stratified squamous epithelia, dendrites as well as in histiocytic reticular cells and in
the reserve cells in prostata. (Davies, M.E. and Barrett, A.J.. Immunolocalization of human cysteins in neutrophils and lymphocytes. Histochemistry, 80:373-377, 1984). In addition to the natural cysteine proteinase inhibitors, also synthetic peptide cysteine proteinase inhibitors have been made. (Bromme, D., Rinne, R., Kirschke, H.: Tight-binding inhibition of cathepsin S by cystatins . Bio ed Biochim Acta 1991:150:631-635). Cysteine proteinase inhibitors are also found in the skin of poikilothermic animals, such as salmon and river lamprey (for example the recently found so called troms family; own unpublished results of the inventor' s team) . Cysteine proteinase inhibitors are known to inhibit the reproduction of microbes (bacteria and viruses) and/or the associated destruction of tissues (Rinne, A. : Cystatin A. Human protein data [A. Haeberli, editor, VCH Verlag, Weinheim] , 3. Installment 1995; Bjδrck, L., Grubb, A. and Kjellen, L. (1990) Cystatin C, a human proteinase inhibitor, blocks replication of Herpes simplex virus. J Virol 64, 941-943; Bjδrck, L., Akesson, P., Bohus , M., Trojnar, J.,
Abrahamson, M. , Olafson, I., and Grubb, A. (1989) Bacterial growth blocked by a synthetic peptide based on the structure of a human proteinase inhibitor. Nature 337, 385-386; Bjδrklund, H.V., Johansson, T.R., and Rinne, A. Rhabdovirus-induced apoptosis in a fish cell line is inhibited by a human endogenous acid cystein proteinase inhibitor. J Virol, 71:5658-5662, 1997; Ni J; Fernandez MA; Danielsson L; Chillakuru RA; Zhang JL; Grubb A; Su J; Gentz R; Abrahamson M: "Cystatin F is a glycosylated human low molecular weight cysteine proteinase inhibitor", Journal of Biological Chemistry, 1998, V 273, N38 (Sep 18), p. 24797- 24804) .
Of course, the human cysteine proteinase inhibitors found endogenously in the mouth (in the saliva and the mucosa) make a contribution to the inhibition of cysteine proteinases. However, the ACPI, for example, is known to be reduced or lost in an inflamed or cariotic mouth (Finnish
6 patent FI 96743 and inventor's own unpublished results).
Controlled release of an active agent from a pharmaceutical preparation
Controlling the rate and timing of the release of an active agent, generally a medicament, from a pharmaceutical preparation is a common practice in the development of drugs. The controlled release of an active agent is applied, for example, for preparations which do not withstand the action of the gastric juice. In that case a tablet is coated with a membrane which is not degraded until in the small intestine, in which case the drug can be protected against the deleterious effects of the acidic environment in the stomach. Many kinds of pharmaceutical preparations, in which the drug is released at a controlled rate, are also used in ophthalmology. The aim in their development has been to obtain a relatively slow release of the drug from the carrier. However, by the choice of a suitable form of preparation it is possible to control the rate of release in both directions. When the so called pro- drugs are used, the drug itself is bound to a carrier in such a manner that the complex is inactive and the activation does not occur until, for example, at the mucosa upon the cleavage of the bond between the carrier and the drug. Examples of such preparations are among others piv- and bacampicillin, both of which are clinically used preparations . The drug can also be activated by the pH in its environment. A well known example of this is omeprazole, a drug which is used in the treatment of gastric ulcer and which does not become active until upon contact with the hydrogen ion-producing parietal cells in the stomach.
The pharmaceutical dosage form of a drug can be designed to release the active agent relatively quickly in the oral mucosa. For example, upon the delivery of nitroglyserin as a resoriblet or a sublingual tablet, the originally solid
preparation disintegrates on the oral mucosa at a conspicuously fast rate so that the effect of the drug in the bloodstream is obtained as early as in 2-3 minutes. For the treatment of gastric ulcer there is available on the market among others Pepcidin Rapitab tablet (MSD), which rapidly releases the drug upon contact with oral excretions; the dissolution of the tablet on the oral mucosa takes only a few tens of seconds . A two-layered tablet allows the release of desired pharmacologically active agents in a chosen order. The outer layer of the tablet can be adapted to dissolve rapidly upon contact with oral excretions, whereupon the agent mixed therein is delivered quickly in the mouth; by employing excipients in the core of the tablet, the core can be adapted to dissolve at a slower rate, which results in a slower release and a slower onset of the effects of the active agents mixed therein. By using normal pharmaceutical practice it is also possible to produce preparations comprising more than two layers, which result in the ability to control the respective order of release and the onset of the effects of the active agent when the product is held on the oral mucous membrane .
Liposome technique
The mixing of molecules with hydrophilic and hydrophobic properties in an aqueous solution produces vesicles, known as liposomes. The liposomes allow the encapsulation of, among other things, drugs and many other biologically active agents within their interior, thereby making it possible to have a desired influence on the spectrum of actions of the respective agent in the body. The composition of the liposomal membrane, encapsulation efficiency or the ability of the liposome to encapsulate the desired active agent within its interior, the stability of the preparation, the release rate of the active agent, the distribution of the liposomal preparation within the body, the size of the liposome and its surface electric
8 charge contribute, besides of other factors, to the properties of the complex composed of the liposome and the encapsulated agent, thereby making the application of the combination in various situations flexible. Insulin can be mentioned as an example of a protein structure which is rather simple to encapsulate in the liposome. On the inner surface of a production vessel a thin membrane can be made of lechitin and cholesterol. The addition of a water-based buffered insulin solution and subsequent shaking results in the formation of insulin-containing liposomes. Various liposome preparations are available commercially and are used widely, for example in skin care products. Catezomes TM (Collaborative Laboratories) can be mentioned as an exemplary product which can be used in the encapsulation of both hydrophilic anf hydrophobic agents and which are specially designed to keep the active agent on the surface of the skin.
The problem associated with the cysteine proteinase preparations in the art
The enzymatic activity of cysteine proteinases has been exploited in the art in a cleaning and whitening toothpaste (Rembrandt®, Yotuel®) . In this tootpaste papain from the papaya-fruit has been used as a cysteine proteinase. Papain is a foreign protein to the mammalian body and in long term use of it is known to cause allergy at least (observations made by Ari Rinne in his own laboratory during the years 1975-1998 and general lecture knowledge in the medical faculties, e.g. in eye diseases). In addition, papain is active at an acidic pH but not at a physiological pH in the oral area, as for example body' s own cathepsin S.
Similarly, Yotuel® chewing gum, which contains, among other things, xylitol and papain as a whitening agent, has appeared on the market quite recently.
SUMMARY OF THE INVENTION
The invention concerns a method for cleaning of a person's body parts, except for the teeth, or objects coming into contact with said body parts. In the method, the body' s own cysteine proteinase is contacted with said body part or object.
According to another aspect, the invention concerns a hygiene product intended for cleaning of a person' s body parts, except for the teeth, or objects coming into contact with said body parts, said product containing a cysteine proteinase and a necessary carrier. According to the invention, the cysteine proteinase is one of the body's own cysteine proteinases .
According to a third aspect, the invention concerns a method for cleaning of a person's body parts or objects coming into contact with said body parts. The method is characterized in that an agent activating the body' s own cysteine proteinase is contacted with said body part or object.
According to still a fourth aspect, the invention concerns a hygiene product intended for cleaning of a person' s body parts or objects coming into contact with said body parts. The product is characterized in that it comprises an agent activating the body's own cysteine proteinase and optionally a carrier.
DESCRIPTION OF THE INVENTION
The terms " natural" cysteine proteinase or cysteine proteinase inhibitor and "the body' s own" cysteine proteinase or cysteine proteinase inhibitor refer to substances purified by techniques in the art of protein chemistry as well as produced by molecular biological techniques . Most of such cysteine proteinases belong to the cathepsin, caspasine or calpain family.
10
According to one embodiment of the invention, in the method the body's own cysteine proteinase is brought into contact with the object to be cleaned. If desired, the cysteine proteinase is activated by contacting it with a sulfhydryl reagent, such as cysteine. For the activation, it is also of importance that the pH is suitable to the activation of the respective cysteine proteinase. The pH is suitably adjusted, if necessary, in order to activate the cysteine proteinase. Various procedures are available for the activation.
The cysteine proteinase can also be pre-activated .
If desired, cysteine proteinase activity can be blocked by delivering a pH-controlling agent and/or body' s own cysteine proteinase inhibitor onto the object to be cleaned, at a moment when the cysteine proteinase has acted sufficiently long. Alternatively, the action of the cysteine proteinase can be blocked by releasing onto the object to be cleaned, a pH-controlling agent given concurrently with the cysteine proteinase and/or body' s own cysteine proteinase inhibitor.
The hygiene product according to the invention, intended for cleaning the person's body parts or objects coming into contact with said body parts, said product comprising the body' s own cysteine proteinase and a necessary carrier, can, in principle, be of any type. For example, it can be solid; a solution; a suspension or semi-solid.
According to the preferred embodiment, the product comprises also a sulfhydryl reagent or some other reductant necessary for the activation of the cysteine proteinase. If the ambient pH of the object to be cleaned is unfavourable for the activation of the cysteine proteinase it is advisable that the product also contains a pH-controlling substance.
11
If desired, to the product can also be added an agent which blocks the cysteine proteinase and which is released after the completion of the desired duration of action of the cysteine proteinase. The agent which blocks the cysteine proteinase can be a pH-controlling agent (or an agent which blocks the active state of the cysteine proteinase) or any of the body' s own cysteine proteinase inhibitors .
The release of the agent which blocks the cysteine proteinase after a specified time has elapsed can be accomplished by employing any of the techniques known in the art of controlled release.
The product can also comprise many of the body' s own cysteine proteinases and possibly many of the body' s own cysteine proteinase inhibitors .
According to another embodiment of the method according to this invention, the object to be cleaned, which is a person's body part, or a object co ing into contact with said body part, is contacted with an agent activating the body's own cysteine proteinase. In this alternative, no cysteine proteinase is added. Preferably, as activating agent is used a reducing agent, for example a sulfhydryl reagent, such as cysteine or calcium. It is also important that the pH is suitable for the activation of the cysteine proteinase. If necessary, the pH can be adjusted to a suitable level for the activation of cysteine proteinase. As activating agents other suitable agents can also be used.
The plain activating agent is, for example, suitable for cleaning of a person's teeth. The word "cleaning" shall, as far as teeth are concerned, also be understood to encomapss "whitening" .
If desired, cysteine proteinase activity can be blocked by delivering a pH-controlling agent and/or body' s own
12 cysteine proteinase inhibitor onto the object to be cleaned, at a moment when the cysteine proteinase has acted sufficiently long. Alternatively, the action of the cysteine proteinase can be blocked by releasing onto the object to be cleaned, a pH-controlling agent given concurrently with the cysteine proteinase and/or body' s own cysteine proteinase inhibitor.
The hygiene product according to the invention, intended for cleaning the person's body parts such as teeth, said product comprising an agent activating the body' s own cysteine proteinase, and optionally a necessary carrier, can, in principle, be of any type. For example, it can be solid such as a chewing gum or tablet; a solution; a suspension or semi-solid such as, for example, a toothpaste.
According to a preferred embodiment, the product comprises as activating agent a sulfhydryl reagent or some other reductant. If the ambient pH of the object to be cleaned is unfavourable for the activation of the cysteine proteinase, it is advisable that the product also contains a pH- controlling substance.
If desired, to the product can also be added an agent which blocks the cysteine proteinase and which is released after the completion of the desired duration of action of the cysteine proteinase. The agent which blocks the cysteine proteinase can be a pH-controlling agent (or an agent which blocks the active state of the cysteine proteinase) or any of the body' s own cysteine proteinase inhibitors .
The release of the agent which blocks the cysteine proteinase after a specified time has elapsed can be accomplished by employing any of the techniques known in the art of controlled release.
The methods according to the invention are especially
13 useful for cleaning of the oral regions or the skin, or for cleaning of prostheses, various treatment devices etc. Among the fields of use for the active agents (the body's own cysteine proteinase and/or an activating agent therefor) are: sweets, such as chewing gum; foodstuffs and drinks; chewing tablets; mouthwash for oral hygiene; cleaning emulsions for the skin and the hair; cottons and towels for cleaning of the skin; liquids and powders for the cleaning of prostheses, for example dental prostheses; auxiliary devices such as contact lenses, glases, hearing aids, items of clothing, vessels and (medical or dental) instruments. For example, the disk for cleaning and whitening of teeth, located at the tip of the dentist's drill, can be coated with the proteins in question. A usual tooth brush or bath sponge can also be coated with these agents .
The invention can be descibed in more detail by reference to the following examples:
To a paste, solution, or solid product is added natural human cathepsin S (this can be produced for example by molecular biological techniques), which is active at the physiological pH prevailing on the object to be cleaned. A further addition is a sulfhydryl reagent, for example cysteine, which is released on the object to be cleaned, from granules, see below. With the assistance of an externally added sulfhydryl reagent cathepsin S becomes biologically active and performs proteolytic cleaning of the object to be cleaned. The long-term and possibly deleterious proteolytic activity of cathepsin S is inhibited with the release after a specified time on the object to be cleaned of (a) human cysteine proteinase inhibitor(s) added to the product. Also the action of cysteine proteinase inhibitors in inhibiting the growth of pathogenic micro-organisms, which is known in the art, is also taken advantage of. In particular, as cysteine proteinase inhibitors, known natural human cysteine
14 proteinase inhibitors are employed.
Alternatively, the products can also be prepared so that, for example, human cathepsins B, H or L are used as the natural cysteine proteinase, in which case the product has to be made such that the excipients in the product convert the object to be cleaned transiently acidic, under which conditions the respective cathepsins are biologically active. Of course, also so called "new" recently discovered human cysteine cathepsins, such as 0, U, K etc., can be used once their activity ranges have been exactly determined.
All the proteins (cysteine proteinases and their inhibitors) associated with this invention can be produced by purifying them directly from human tissues or by using molecular biological techniques.
The pH in the mixture and in the object to be cleaned should return again to a physiological value secondarily in connection with the release of the inhibitor. The potency of the respective exogenously added natural cathepsins is exhausted and the natural externally added inhibitors together with the inhibitors optionally already present in the object to be cleaned, secure additionally the cessation of the proteolysis, which is deleterious in the body. The excipients in question (cysteine proteinases and their inhibitors) are added to products which are known per se (for example cleaning liquids for contact lenses). Many variations can be made in the basic products . Modifications and fine-tuning can be made by using cysteine proteinases which differ somewhat in their biological properties. Similarly, representatives of various cysteine proteinase inhibitor families can be used.
Cathepsins and the sulfhydryl reagent are packaged into the different phases of the products by employing for example liposomes (the pH is dependent upon the cathepsin
15 employed), from which these are released at a controlled rate as the conditions in the environment change upon bringing the liposomes into contact with the object to be cleaned. The retention time on the object to be cleaned is dependent among other things on their electric charge
(positive, neutral, negative). Thus the retention time can be controlled according to the desired goal. (S olin, G., Okumoto, M. , Feiler, S., Condon, D.: Idoxuridine-liposomal therapy for herpes simplex keratitis . Am J Ophthalmol 1981:91:220-225; Meisner, D., Pringle, J., Mezei, M. :
Liposomal ophthalmic drug delivery. III. Pharmacodynamic and biodisposition studies of atropine . Int J Pharm 1989:55:105-113; Barber, R.F., Shek, P.N.: Tear-induced release of liposome-entrapped agents. Int J Pharm 1990:60:219-227; Lee, V.H.L., Urrea , P.T., Smith, R.E., Schantzlin, D.J. : Ocular drug bioavailability from topically applied liposomes . Surv Ophthalmol 1985:29:335-348; Guo, L.S.S., Redema , C.T., Radhakrisnan, R. : Bioadhesive liposomes in ophthalmic delivery. Invest Ophthalmol Vis Sci 1987:28:72; Finne, U.: Basic salts modify timolol delivery in ocular inserts of alkyl monoesters of poly(vinyl methyl ether-maleic anhydride). University of Kuopio, National Agency for Welfare and Health, Research Reports 15, Helsinki 1991). The secondarily released cysteine proteinase inhibitor is bound for example to a mucoadhesive polymer (the physiological or slightly basic pH of the object to be cleaned). These are synthetic or natural macromolecules [Longer, M.A. , Robinson, J.R.: Fundamental aspects of bioadhesion. Pharm Int 1986:7:114-117; Hui , H.W., Robinson, J.R.: Ocular delivery of progesterone using a bioadhesive polymer. Int J Pharm 1985:26:203-213; Saettone, M.F., Chetoni , P., Torracca, M.T., Burgalassi, S., Giannaccini, B.: Evaluation of muco-adhesive properties and in vivo activity of ophthalmic vehicles based on hyaluronic acid. Int J Pharm 1989:51:203-212; Robinson, J.R.: Bioadhesive compositions and methods therewith. US Patent 1991:4,983,392; Finne, U.: Basic salts modify timolol
16 delivery in ocular inserts of alkyl monoesters of poly(vinyl methyl ether-maleic anhydride). University of Kuopio, National Agency for Welfare and Health, Research Reports 15, Helsinki 1991; Lahdes K: Systemic absorption and effects of topically applied ocular anticholinergic drugs, Annales Universitatis Turkuensis Ser. D, Tom. 218, Turku 1996; Huupponen, R. , Kaila, T., Saettone, M.F., Monti, D., Iisalo, E., Salminen, L., Oksala, 0.: The effect of some macromolecular ionic complexes on the pharmacokinetics and dynamics of ocular cyclopentolate in rabbits. J Ocul Pharmacol 1992:8:59-67]. This provides a longer lasting inhibitor on the mucous membrane, whereupon the known ability of the cysteine proteinase inhibitors to inhibit the tissue defects caused by for example pathogenic organisms (disease processes) is also specifically enhanced. Liposomes or other similar controlled release structures having mucoadhesive properties can also be used in the package.
A paced action can be obtained also by using a so called hydrogel, from which the active agent is slowly released by diffusion (Kupferman, A., Ryan, W.J., Leibowitz, H.M.: Prolongation of anti-inflammatory effect of prednisolone acetate. Influence of formulation in high-viscosity gel. Arch Ophthalmol 1981:99:2028-2029; Lewis, R.A. , Schoenwald, R.D., Eller, M.G. , Barfknecht, C.F., Phelps , CD.:
Ethoxzolamide analogue gel. A topical carbonic anhydrase inhibitor. Arch Ophthamol 1984:102:1821-1824; Urtti, A.: Silman uudet laakemuodot . In: Biofarmasia 1986 Kuopio. Gummerus Oy, Jyvaskyla 1986:44-53). If various matrices (carrier phases) are included in the same preparation, the release of active agents admixed therein is accomplished with distinct rates and different durations of existence on the object to be cleaned.
If the product is finished into a dry product, the active agents can be packaged in a layered manner. The pace of the release can be controlled to obtain a more defined and
17 clear result by packaging the active agents in different materials .
EXAMPLE
Paste
The composition of a paste can be the following:
1. Abrasive and polishing agents, for example calcium carbonate or tricalcium phosphate, ca 50 %
2. Binder, for example aqueous silica or sodium carboxymethylcellulose, ca 3 % 3. A foam-producing non-soap-based detergent, ca 2 %
4. A soap-based detergent c . 8 %
5. Humidifiers, for example sorbitol or glycerol, ca 30 %
6. Flavor and aroma, for example saccharine or xylitol (according to current trend salmiac), ca 1 % 7. 0,001 % cysteine cathepsin as such or packaged into liposomes
8. 0,0001 % cysteine packaged for example in liposomes
9. 0,001 % cysteine proteinase inhibitor affixed into a mucoadhesive polymer 10. balance water.
The invention has significant advantages as compared to the products of prior art:
- in the same product, natural, exogenously delivered cysteine proteinases are used to obtain cleaning and whitening and, on the other hand, the excessive and probably deleterious action of these cysteine proteinases upon tissues is blocked by using exogenously added natural cysteine proteinase inhibitors . The enzyme kinetics of these proteins is well known
- slightly differing natural cysteine proteinases and their inibitors can be used, and therefore the action spectrum
becomes wide and the influence on the control can be more easily accomplished
- the temporal control of the active agents has been obtained so that it is sensitive and accurate by employing liposomes, mucoadhesive polymers and hydrogel or other applications of the controlled-release technique
- the favourable (balancing, anti-inflammatory and antidestructive) effect of the natural inhibitor is not removed immediately from the mucosa
- in the same product, it is possible to exploit in a controlled manner the beneficial effects of both the cysteine proteinase and their inhibitors
- both the cysteine proteinases and their inhibitors delivered externally into the body are body' s own proteins, therefore the risk of sensitization is small; this is in contrast to the use of the corresponding proteinases and their inhibitors, which are recognized as foreign by the body and derived for example from the plant kingdom.
The above mentioned embodiments of this invention are merely examples of the practice of the idea according to the invention. It should be apparent to those skilled in the art that the invention can have various embodiments , which are within the scope of the following claims.
Claims
1. A method for cleaning of a person's body parts, except for the teeth, or objects coming into contact with said body parts, characterized in that a body' s own cysteine proteinase is contacted with said body part or object.
2. The method according to claim 1, characterized in that the cysteine proteinase is activated by contacting it with a sulfhydryl reagent or with an another reducing agent.
3. The method according to claim 2, characterized in that the pH is suitably adjusted, if necessary, in order to activate the cysteine proteinase.
4. The method according to claim 1, 2 or 3, characterized in that the activity of the cysteine proteinase is blocked by introducing onto the object to be cleaned a pH- controlling agent and/or a body' s own cysteine proteinase inhibitor.
5. The method according to claim 1, 2 or 3, characterized in that the activity of the cysteine proteinase is blocked by introducing simultaneously with the cysteine proteinase onto the object to be cleaned a pH-controlling agent and/or a body's own cysteine proteinase inhibitor.
6. A hygiene product, which is intended for the cleaning of a person's body parts, except for the teeth, or objects coming into contact with said body parts, said product comprising a cysteine proteinase and a necessary carrier, characterized in that the cysteine proteinase is one of the body' s own cysteine proteinases .
7. The product according to claim 6, characterized in that it comprises a sulfhydryl reagent necessary for the activation of the cysteine proteinase and optionally a pH- 20 controlling agent.
8. The product according to claim 6 or 7 , characterized in that it also comprises an agent for blocking the activity of cysteine proteinase, said agent being released after the desired duration of action of the cysteine proteinase.
9. The product according to claim 8, characterized in that the agent for blocking the activity of cysteine proteinase is a pH-controlling agent.
10. The product according to claim 8, characterized in that the agent for blocking the activity of the cysteine proteinase is a body' s own cysteine proteinase inhibitor.
11. The product according to any of the claims 6 - 10, characterized in that it comprises several of the body' s own natural cysteine proteinases and optionally several of the body's own natural cysteine proteinase inhibitors.
12. The product according to any of the claims 6 - 11, characterized in that it is solid, a solution; a suspension or semisolid.
13. The product according to any of the claims 6 - 12, characterized in that it is intended for cleaning of contact lenses .
14. A method for cleaning of a person's body parts or objects coming into contact with said body parts, characterized in that an agent activating the body' s own cysteine proteinase is contacted with said body part or object .
15. The method according to claim 14, characterized in that as activating agent is used a sulfhydryl reagent or another reducing agent, such as cystein or Ca . 21
16. The method according to claim 15, characterized in that the pH is adjusted to a suitable level, if necessary, in order to activate the cysteine proteinase.
17. The method according to claim 14, 15 or 16, characterized in that the activity of the cysteine proteinase is blocked by adding onto the object to be cleaned, a pH-controlling agent and/or a body' s own cysteine proteinase inhibitor.
18. The method according to any of the claims 14 - 17, characterized in that the body parts to be cleaned are the person ' s teeth .
19. A hygiene product, which is intended for the cleaning of a person's body parts, or objects coming into contact with said body parts, characterized in that it comprises an agent activating the body's own cysteine proteinase, and optionally a carrier.
20. The product according to claim 19, characterized in that it comprises a sulfhydryl reagent as activating agent, and optionally a pH-controlling agent.
21. The product according to claim 19 or 20, characterized in that it also comprises an agent for blocking the activity of cysteine proteinase, said agent being released after the desired duration of action of the cysteine proteinase .
22. The product according to claim 21, characterized in that the agent for blocking the activity of cysteine proteinase is a pH-controlling agent.
23. The product according to claim 21, characterized in that the agent for blocking the activit of the cysteine proteinase is a body' s own cysteine proteinase inhibitor. 22
24. The product according to any of the claims 19 - 23, characterized in that it is solid, a solution, a suspension or semisolid.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FI980143 | 1998-01-22 | ||
FI980143A FI980143A0 (en) | 1998-01-22 | 1998-01-22 | Foerfarande och produkt Foer rengoering av biologiska delar (saosom munomraodet, huden) av en person och Foer rengoering av foeremaol (saosom proteser, behandlingsinstrument) |
PCT/FI1999/000040 WO1999037283A1 (en) | 1998-01-22 | 1999-01-21 | Method and device for cleaning of parts of the human body or objects coming into contact with them |
Publications (1)
Publication Number | Publication Date |
---|---|
EP1054661A1 true EP1054661A1 (en) | 2000-11-29 |
Family
ID=8550508
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP99900899A Withdrawn EP1054661A1 (en) | 1998-01-22 | 1999-01-21 | Method and device for cleaning of parts of the human body or objects coming into contact with them |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP1054661A1 (en) |
FI (1) | FI980143A0 (en) |
WO (1) | WO1999037283A1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FI970012A (en) * | 1997-01-03 | 1998-07-04 | Rinne Ari E | Use of cysteine proteinases and their inhibitors in oral hygiene products |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA959764A (en) * | 1971-02-09 | 1974-12-24 | Morton Pader | Dentifrice |
FR2345998A1 (en) * | 1976-04-02 | 1977-10-28 | Manceau Laboratoires | Dentifrice compsn. contg. enzyme fixed on resin - released by reducing agent in other separate component with water contact |
JPS5879913A (en) * | 1981-11-09 | 1983-05-13 | Taizo Ayukawa | Hair tonic composition |
US5340922B1 (en) * | 1988-05-31 | 1999-11-02 | Mclean Hospital Corp | Neural calcium-activated neutral proteinase inhibitors |
CA2002820A1 (en) * | 1988-11-18 | 1990-05-18 | Kazunori Hanada | Pharmaceutical use for cystatins |
GB9319104D0 (en) * | 1993-09-15 | 1993-11-03 | Unilever Plc | Skin care method & composition |
FI96743C (en) * | 1994-08-29 | 1996-08-26 | Ari Ensio Rinne | Use of a cysteine proteinase inhibitor in oral hygiene and confectionery products |
FI970012A (en) * | 1997-01-03 | 1998-07-04 | Rinne Ari E | Use of cysteine proteinases and their inhibitors in oral hygiene products |
-
1998
- 1998-01-22 FI FI980143A patent/FI980143A0/en not_active Application Discontinuation
-
1999
- 1999-01-21 EP EP99900899A patent/EP1054661A1/en not_active Withdrawn
- 1999-01-21 WO PCT/FI1999/000040 patent/WO1999037283A1/en not_active Application Discontinuation
Non-Patent Citations (1)
Title |
---|
See references of WO9937283A1 * |
Also Published As
Publication number | Publication date |
---|---|
FI980143A0 (en) | 1998-01-22 |
WO1999037283A1 (en) | 1999-07-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0969800B1 (en) | A method and product for cleaning and/or whitening of teeth | |
ES2237789T3 (en) | USE OF COMPOSITIONS THAT INCLUDE STABILIZING ENZYMES. | |
ES2281911T3 (en) | COMPOSITIONS TO CONTROL LEVELS (EH) OF MICROBIAL OXIDATION-REDUCTION OF THE ORAL CAVITY. | |
US20190183989A1 (en) | Use of serine protease inhibitors in the treatment of skin diseases | |
ES2282314T3 (en) | ORAL COMPOSITION THAT ALLOWS A GREATER ELIMINATION OF TEETH SPOTS. | |
Herlofson et al. | Oral mucosal desquamation caused by two toothpaste detergents in an experimental model | |
AU2003237194B2 (en) | Antibacterial dentifrice exhibiting antiplaque and breath freshening properties | |
US20030158111A1 (en) | Methods and products for oral care | |
KR20000016215A (en) | Mouthwash composition comprising cetylpyridinium chloride and an amphoteric surfactant | |
JP2000500513A (en) | Enzymes with low isoelectric point for use in contact lens cleaning | |
AU697576B2 (en) | Tooth whitening preparations | |
CN1688280B (en) | Antiplaque enzyme containing dual component composition | |
Newman | Modes of application of anti‐plaque chemicals | |
US20010002252A1 (en) | Tooth whitening preparations | |
US20210121380A1 (en) | Amino Acid Containing Oral Care Composition for Treating Caries By Reducing Lactic Acid Release in Oral Biofilms | |
ES2417493T3 (en) | Oral compositions for the prevention and reduction of bacterial adhesion to oral surfaces | |
JPH0768111B2 (en) | Oral composition | |
EP1054661A1 (en) | Method and device for cleaning of parts of the human body or objects coming into contact with them | |
EP0258186B1 (en) | Enzyme containing denture cleansers and method of use | |
JP3396934B2 (en) | Denture cleaner | |
NZ547077A (en) | An oral product comprising an amount of a metal-binding peptide which is effective for oral care | |
WO2021225469A1 (en) | Biologically active complex, and toothpaste and mouthwash based thereon | |
JPH03261716A (en) | Composition for oral cavity application | |
KR20050046050A (en) | Liquid-crystal tooth whitener | |
NZ563229A (en) | Methods and products for oral care |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20000821 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): BE DE DK FI FR GB IT NL |
|
17Q | First examination report despatched |
Effective date: 20021120 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20030401 |